2Foa R, Guarim A, Gansbacher B. IL -2 treatment for cancer: from biology to therapy[J]. Br J Cancer, 1992,66(4) : 992.
3Maas RA, Dulleus HFJ, Otter WD. Interleukin -2 in cancer treatment : disappointing or (still) promoising? a review[ J ]. Cancer Immunol Immunother ,1993,36(2) :141.
4Astoul P, Viallat J R, Laurent J C, et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion[ J].Chest, 1993,103 ( 1 ) : 209.
5Rosenherg SA. A progress report on the treatment of 157 patients with advanced cancer using LAK cellsand rIL - 2 or high - dose of IL-2 alone[J]. V Engl J Med,1987,316(4):889.
6Pizza G, V iza D, Vinci CD, et all. Intra -lymphatic adm instration of interleukin - 2 ( IL - 2 ) in cancer patients : a pilot study[J]. LymphokineRes, 1988,7(1):45.
7Vaage J. Local interleukin -2 therapy ofmouse mammary tumors of various immunogenicities [ J ]. Cancer Res, 1988,48 ( 11 ) : 2193.
8Yasumoto K, Mivazaki K, Nagashima A, et aL Induction of lymphokine - activated killer cells by intrapleural instillations of recombinant interleukin -2 in patients with malignant pleurisy due to lung cancer[ J]. Cancer Res, 1987,47(8) : 2184.
9Ratto G B, Melioli G, Zino P, et al. Immunotherapy with the use of tumor - infiltrating lymphocytes and interleukin - 2 as adjuvant treatment in stage Ⅲ non - small - cell lung cancer. A pilot study[J]. J Thorac Cardiovasc Surg,1995,109(6) : 1212.
